How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)
Your mitochondria are running two separate maintenance systems at the same time, and most people have no idea those systems even exist, let alone that they can be supported simultaneously.
One system is structural. The inner membrane of your mitochondria needs to stay physically organized for the electron transport chain to work efficiently, and when that membrane degrades, energy output drops and oxidative stress rises. The other system is regulatory. Your mitochondria actually produce their own signaling molecules that travel to the nucleus and change how genes are expressed, which affects how your cells handle fuel, stress, and aging over time.
SS-31 targets the first system. MOTS-c targets the second. They do not compete for the same binding site, they do not interfere with each other's mechanism, and the case for combining them is built on that non-overlap.
Start with SS-31 to understand why daily dosing matters.
SS-31 works by binding to something called cardiolipin, which is a phospholipid, meaning a fat molecule, that sits almost exclusively on the inner mitochondrial membrane. Cardiolipin is what holds the protein complexes of the electron transport chain in the right physical arrangement so electrons can move efficiently from one complex to the next. When cardiolipin gets oxidized or disorganized, those complexes drift apart, electron transfer slows, and instead of producing ATP you produce more reactive oxygen species as a byproduct.
SS-31 binds to cardiolipin and stabilizes it. That stabilization allows the complexes to reorganize, electron flow improves, and ATP production goes back up while oxidative stress comes down. The reason SS-31 can do this at very low doses is that it concentrates roughly five thousand fold at the inner membrane relative to plasma levels, so even a small circulating amount reaches therapeutic concentration right where it needs to act.
The plasma half-life of SS-31 is about two hours, which means the peptide itself clears quickly, but the structural repair it supports takes weeks to accumulate. That is why you run it daily. You are not chasing a pharmacological effect tied to plasma levels. You are giving the membrane consistent support while it undergoes gradual reorganization.
On dosing, a phase 2 trial comparing 4 milligrams to 40 milligrams found no measurable advantage at the higher dose, which tells you the concentration effect at the membrane means you hit a ceiling early. The working range is 1 to 5 milligrams per day, with 2 milligrams being where most people tend to find the balance between effect and cost.
MOTS-c operates differently in almost every way.
MOTS-c is something called a mitochondrial-derived peptide, which means it is encoded in mitochondrial DNA and produced inside mitochondria themselves rather than in the nucleus like most proteins. Under normal conditions your mitochondria release it in response to metabolic stress, particularly during exercise, and it travels to the nucleus where it changes gene expression through pathways involving something called AMPK, which is essentially a cellular fuel sensor that shifts the cell toward more efficient energy use when resources are scarce.
When MOTS-c activates AMPK, it triggers a cascade that improves how mitochondria process fuel, reduces the production of reactive oxygen species, and supports something called mitochondrial biogenesis, which is the process of building new mitochondria. Research published in Nature Communications showed that in aging animals, endogenous MOTS-c production declines significantly, and that physical decline tracked with that reduction. Restoring MOTS-c levels reversed age-related muscle deterioration even in older animals.
Because MOTS-c works through gene expression changes rather than through direct binding to a structural target, it does not need to be present continuously. A study confirmed that three times per week dosing maintained all the benefits seen with daily loading, because the downstream gene expression changes outlast the peptide's presence in circulation by a significant margin. Monday, Wednesday, Friday at 5 to 15 milligrams per week covers the full effect.
Now, the question people ask is whether you need to cycle off at all.
The cycling concern with most compounds comes from receptor desensitization, where repeated stimulation of a receptor causes the cell to reduce the number of receptors it expresses, so the same dose produces a weaker effect over time. SS-31 does not bind to a receptor. It binds to a structural lipid, and there is no evidence that cardiolipin downregulates in response to SS-31 binding. The longest continuous human trial ran SS-31 at 40 milligrams daily for 168 weeks and found progressive improvement throughout with no tolerance development.
MOTS-c has no feedback loop in the way that exogenous testosterone suppresses endogenous testosterone production. It is not a hormone that the body regulates through a negative feedback axis. It is a stress-response peptide, and animal research has shown sustained benefits with lifelong administration.
The honest reason cycling is still recommended is that there is no long-term human safety data at these doses. That is the actual gap. The mechanism does not predict tolerance, and the available data does not show it, but the absence of a 168-week MOTS-c human trial means precaution is reasonable.
For a starting protocol: 2 milligrams SS-31 daily and 10 milligrams MOTS-c per week across Monday, Wednesday, and Friday. If you are new to either compound, cut both in half for the first four weeks. If you are managing significant age-related functional decline, the upper end is 5 milligrams SS-31 daily and 15 milligrams MOTS-c per week. Run 8 to 12 weeks, take 4 to 8 weeks off, and understand that the off cycle is precautionary rather than mechanistically required.
One thing to be clear about: no human study has ever tested this combination. The protocol is derived from how each compound works independently and the fact that their mechanisms do not intersect. The closest published data is a mouse study showing synergistic benefit when SS-31 was combined with NMN in aged hearts, which at least confirms that compounds targeting different mitochondrial pathways simultaneously can produce additive effects. But that is not the same as a human trial of this specific stack.
The reason this matters is that most people think about mitochondrial health as a single dial you can turn up or down, when really it is at least two distinct systems that age and fail independently and respond to different interventions. Fixing membrane structure does not fix metabolic signaling, and fixing metabolic signaling does not fix membrane structure. They are separate problems, and treating them separately but simultaneously is the logic the combination is built on.
References
- Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
- Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
- Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
- Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.